Bladder Cancer - Results from #360

National audit of patient reported experience of radical cystectomy for bladder cancer pathways. October 18, 2024

Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. October 18, 2024

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial October 17, 2024

Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. October 17, 2024

Effects of Intraoperative Opioid Use and a Combined Anesthesia Protocol in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder-A Single-Center Experience. October 17, 2024

The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond. October 17, 2024

Development of a new radical cystectomy surveillance protocol and nurse-led cystectomy follow-up clinic in Australia. October 17, 2024

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec October 16, 2024

Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer. October 16, 2024

The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial. October 16, 2024

Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach October 15, 2024

Oncologic outcomes of pelvic organ-preserving radical cystectomy vs. Standard radical cystectomy: A systematic review and meta-analysis. October 15, 2024

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. October 15, 2024

Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles. October 14, 2024

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor. October 14, 2024

Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer. October 14, 2024

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort. October 11, 2024

Novel intravesical therapies and delivery systems for the management of bladder cancer. October 11, 2024

Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients. October 10, 2024

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. October 10, 2024

Page 19 of 535